The article discusses that Cabazitaxel (Jevtana) has approved as third-line therapy for patients with metastatic castration-resistant prostate cancer (CRPC) after treatment with docetaxel and an androgen receptor inhibitor. It mentions that new phase 2 clinical trial shows that the radionuclide therapy that targets the prostate-specific membrane antigen (PSMA).